Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07108647

In-Season Prevalence and Management of Hip and Groin Injuries in Competitive Athletes

This study is focused on helping athletes with a common hip condition called femoroacetabular impingement (FAI) syndrome. FAI syndrome occurs when abnormal bone shapes around the hip joint cause friction during movement, leading to pain, reduced performance, and, over time, more serious injury. While this issue is well-studied in male professional athletes, little is known about how it affects female and collegiate athletes, or how to prevent it from worsening.

In this study, athletes diagnosed with FAI syndrome will participate in a 12-week in-season exercise program designed to reduce pain, improve hip strength and movement, and help prevent further injury-all while continuing their regular sports training.

Participants will be randomly assigned to either:

* An exercise group (receiving the intervention), or * A time-and-attention control group (regular check-ins and education).

At the end of the study, the control group will have the option to access the exercise program.

The study will track changes in pain, physical performance, injury recurrence, and athlete satisfaction with the program. This research aims to improve how we manage hip injuries in athletes and help keep them active during the competitive season.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

14 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

Study Rationale Femoroacetabular impingement (FAI) syndrome is a common source of hip pain in athletes participating in cutting, pivoting, and high-impact sports such as soccer, basketball, ice hockey, and ringette. It is characterized by abnormal contact between the femoral head and acetabulum, which may lead to cartilage damage, labral tears, and early osteoarthritis. While research has primarily focused on male professional athletes, there is limited evidence regarding the early management of FAI in younger, female, and collegiate athletes.

Current management strategies often emphasize post-season rehabilitation or surgical interventions, limiting opportunities to explore conservative strategies that allow continued play during the competitive season. This randomized controlled trial (RCT) addresses that gap by evaluating a novel, in-season, 12-week exercise intervention designed to mitigate symptoms, maintain sport participation, and potentially delay or reduce long-term structural damage.

Study Objectives

  • Evaluate the feasibility of implementing an in-season, supervised exercise program in athletes with FAI syndrome.
  • Explore preliminary effectiveness signals on functional outcomes and symptom progression.

Study Design Participants diagnosed with FAI syndrome based on clinical evaluation and symptom history will be randomized to either the intervention or a time-and-attention control group. The intervention group will complete a structured neuromuscular and hip-specific rehabilitation program, while the control group receives educational support and a progressive mobility and recovery (PMR) option during the same 12-week period. Randomization ensures balanced comparison of feasibility and clinical endpoints.

Intervention Protocol

The 12-week intervention focuses on:

  • hip and core strength (e.g., isometric and isotonic exercises targeting hip flexors, abductors, adductors, and gluteals)
  • neuromuscular control (e.g., drills for dynamic stability, pelvic alignment, and functional control)
  • functional progression (e.g., graded loading to meet game demands)

Participants complete the exercises a minimum of 3 times/week, and will be trained at the start of each phase in-person or remotely by a trained clinician. Exercise progression will occur after 4 weeks per phase. Compliance is monitored through weekly questionnaires.

Control Group Protocol: Time and Attention Control + PMR Option The control group will not participate in the structured exercise program but will receive supportive follow-up and access to a three-phase progressive muscle relaxation (PMR) program (audio guided). This design ensures time and engagement are balanced across groups.

The control group protocol includes:

  • scheduled check-ins every 4 weeks with the research team for education and monitoring
  • educational modules on injury prevention, load management, and hip health
  • access to a guided three-phase PMR program

While participation in the PMR component is optional, it offers a low-intensity, restorative alternative without introducing strength training or neuromuscular drills that may overlap with the primary intervention. Control group participants are also offered the full exercise protocol following study completion.

Significance

This is one of the first studies to investigate an in-season, non-operative intervention for FAI syndrome in athletes during competitive play. It targets a high-risk group (female and collegiate athletes), with potential to:

  • fill a critical gap in early-stage, conservative management of FAI syndrome
  • inform future sport- and sex-specific injury prevention programs
  • guide clinical decision-making regarding rehabilitation timing and delivery

Feasibility findings will guide future larger-scale studies, including refined criteria for participant selection, adherence support, and integration within team-based medical models.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • currently identifies as a "competitive athlete" based on the LTAD
  • aged 14-40
  • be free from any significant lower extremity injury (hip, groin, knee, ankle foot) in the past 6 months that resulted in >1 months of time loss or current inability to fully participate in sport at the time of baseline testing

If participants meet the above criteria, can be screened:

  • completed bilateral hip screen, including imaging, and identified as having FAI syndrome with no degenerative joint changes (if meet the remaining criteria,

Exclusion criteria

  • Are currently experiencing or recovering from a lower extremity injury that resulted in >1 month time lost within the past 6 months
  • are pregnant or may become pregnant during the study (due to radiographic imaging exposure)
  • * participants will be excluded from eligibility of RCT if they have evidence of moderate to severe osteoarthritis on imaging (Tönnis grade 2-3)

Treatment and study plan

Progressive Hip Strengthening Program

Other

This 12-week, in-season exercise intervention is designed for athletes with FAI syndrome and consists of three progressive phases.

Phase 1 (Weeks 1-4): Focus on neuromuscular re-education and motor control using low-load exercises to improve hip and core activation, alignment, and stability.

Phase 2 (Weeks 5-8): Targeted strengthening with increased load and movement complexity, emphasizing single-leg control, endurance, and pelvic stability.

Phase 3 (Weeks 9-12): Integration of dynamic control, proprioception, and sport-specific movement patterns to support return to performance.

Exercises target gluteus medius, gluteus maximus, core musculature, and functional movement systems. Participants complete the program >=3 times per week. Weekly questionnaires will monitor symptoms, adherence, and other management (e.g., physiotherapy).

Progressive Muscle Relaxation

Other

Participants in the time and attention control group will complete a 12-week, three-phase progressive muscle relaxation (PMR) program based on the Jacobson method. Phase 1 introduces isolated muscle tensing and relaxing to build awareness of muscle tension and promote body-mind connection. Phase 2 focuses on sequential relaxation of muscle groups, enhancing control and reducing stress. Phase 3 transitions to full-body relaxation through guided breathing and visualization techniques. Sessions are practiced 2-3 times per week using audio guides, with weekly check-ins from study staff. Symptom response, adherence, and participant experience are tracked throughout the season.

Primary outcomes

  1. Proportion of Agreement to Screening

    Time frame: up to 9 months - study time frame is 12 months, with the last participant able to enroll at month 9 to allow for 12 weeks of intervention

    the number of participants whom agree to be screened/the number of participants approached for recruitment

  2. Eligibility Proportion

    Time frame: up to 9 months - study time frame is 12 months, with the last participant able to enroll at month 9 to allow for 12 weeks of intervention

    the number screened positive for inclusion (evidence of FAI syndrome)/number of participants who agreed to be screened (consented)

  3. Consent Proportion

    Time frame: up to 9 months - study time frame is 12 months, with the last participant able to enroll at month 9 to allow for 12 weeks of intervention

    Number of participants screened positive and agreed to participate in intervention/number screened positive for inclusion

  4. Randomization Proportion

    Time frame: up to 9 months - study time frame is 12 months, with the last participant able to enroll at month 9 to allow for 12 weeks of intervention

    The number of participants randomized/the number of participants screened positive and agreed to participate

  5. Trial-Arm Selection Proportion

    Time frame: up to 9 months - study time frame is 12 months, with the last participant able to enroll at month 9 to allow for 12 weeks of intervention

    The number agreed to each trial arm after randomization/the number of participants randomized

  6. Attrition Proportion

    Time frame: up to 9 months - study time frame is 12 months, with the last participant able to enroll at month 9 to allow for 12 weeks of intervention

    The number of participants who drop out of study/number of participants randomized in each arm

Secondary outcomes

  1. International Hip Outcome Tool (iHOT-33)

    Time frame: 12 weeks

    The International Hip Outcome Tool (iHOT-33) is a 33-item patient-reported outcome measure designed to assess the health-related quality of life for young, active individuals with hip disorders. It focuses on how hip problems impact their daily activities, sports, work, and overall well-being. The iHOT-33 is a valuable tool for initial assessments, post-operative follow-ups, and clinical studies related to hip conditions.

  2. Copenhagen Hip and Groin Outcome Tool (HAGOS)

    Time frame: 12 weeks

    Patient-reported questionnaire designed to assess the impact of hip and/or groin problems on physical function and quality of life in young to middle-aged, physically active individuals.

  3. Make (Isometric) Strength Testing of the Hip

    Time frame: 12 weeks

    Strength measures in the hip (N/kg) performed in flexion, abduction, adduction. Measures will be performed pre and post intervention.

  4. Passive Range of Motion

    Time frame: 12 weeks

    Range of motion in degrees at the hip joint in flexion, internal rotation, abduction. Performed pre and post intervention.

  5. Special Test Findings

    Time frame: 12 weeks

    Positive or negative findings on special tests in the hip which reproduce the pain of an injury (out of a maximum of 3). Performed pre and post intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Maitland Martin, MSc, CAT(C), ATC

CONTACT

[email protected]

403-220-5332

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 7, 2025
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.